Scinai Immunotherapeutics Ltd
SCNI
Company Profile
Business description
Scinai Immunotherapeutics Ltd is a biopharmaceutical company with two complementary business units: (i) Scinai R&D, focused on the development of therapeutics in inflammation and immunology, and (ii) the contract development and manufacturing organization (CDMO) business. The CDMO business provides integrated development and manufacturing services to small and emerging biotech companies, supporting clients from early-stage development through clinical-stage production.
Contact
Hadassah Ein Kerem Campus
2nd Floor, Jerusalem BioPark
Jerusalem
ISRT: +972 89302529
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
45
Stocks News & Analysis
stocks
Lithium’s latest drop and what it means for ASX investors
Volatility returns to the lithium market.
stocks
Major ASX miner remains overvalued following production update
Iron ore strength keeps production on track despite lower copper output.
stocks
Ahead of earnings, is Alphabet stock a buy, a sell, or fairly valued?
From Google Cloud to Gemini user retention, here’s what we expect from Alphabet’s earnings report.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,968.50 | 25.00 | 0.28% |
| CAC 40 | 8,340.11 | 1.30 | 0.02% |
| DAX 40 | 24,846.69 | 15.71 | 0.06% |
| Dow JONES (US) | 51,839.26 | 307.16 | -0.59% |
| FTSE 100 | 10,524.76 | 75.61 | -0.71% |
| HKSE | 25,066.65 | 76.40 | -0.30% |
| NASDAQ | 25,508.07 | 12.17 | -0.05% |
| Nikkei 225 | 65,255.68 | 1,114.56 | 1.74% |
| NZX 50 Index | 13,678.86 | 17.17 | -0.13% |
| S&P 500 | 7,443.28 | 14.41 | -0.19% |
| S&P/ASX 200 | 8,785.40 | 28.40 | 0.32% |
| SSE Composite Index | 3,808.97 | 12.69 | 0.33% |